CY1116350T1 - Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπεν - Google Patents
Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπενInfo
- Publication number
- CY1116350T1 CY1116350T1 CY20151100451T CY151100451T CY1116350T1 CY 1116350 T1 CY1116350 T1 CY 1116350T1 CY 20151100451 T CY20151100451 T CY 20151100451T CY 151100451 T CY151100451 T CY 151100451T CY 1116350 T1 CY1116350 T1 CY 1116350T1
- Authority
- CY
- Cyprus
- Prior art keywords
- fluoro
- methanone
- methanesulfonyl
- trifluoro
- pyridin
- Prior art date
Links
- -1 3-Fluoro-5-trifluoromethyl-pyridin-2-yl Chemical group 0.000 title 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 title 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 title 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 title 1
- 229960002216 methylparaben Drugs 0.000 title 1
- 230000001771 impaired effect Effects 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- YUUGYIUSCYNSQR-LBPRGKRZSA-N [4-[3-fluoro-5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-[5-methylsulfonyl-2-[(2s)-1,1,1-trifluoropropan-2-yl]oxyphenyl]methanone Chemical compound FC(F)(F)[C@H](C)OC1=CC=C(S(C)(=O)=O)C=C1C(=O)N1CCN(C=2C(=CC(=CN=2)C(F)(F)F)F)CC1 YUUGYIUSCYNSQR-LBPRGKRZSA-N 0.000 abstract 1
- 230000019771 cognition Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06127269 | 2006-12-28 | ||
| EP07857734.3A EP2114405B1 (en) | 2006-12-28 | 2007-12-18 | methylparaben cocrystal form "A" of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-l-yl]-[5-methanesulfonyl-2- ((S) -2,2,2-trifluoro- 1 -methyl-ethoxy) -phenyl] -methanone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1116350T1 true CY1116350T1 (el) | 2017-03-15 |
Family
ID=38988312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100451T CY1116350T1 (el) | 2006-12-28 | 2015-05-20 | Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπεν |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US20080214561A1 (OSRAM) |
| EP (1) | EP2114405B1 (OSRAM) |
| JP (1) | JP4799666B2 (OSRAM) |
| KR (1) | KR101130146B1 (OSRAM) |
| CN (1) | CN101573114A (OSRAM) |
| AR (1) | AR064545A1 (OSRAM) |
| AU (1) | AU2007341356B2 (OSRAM) |
| BR (1) | BRPI0720829B8 (OSRAM) |
| CA (1) | CA2673667A1 (OSRAM) |
| CL (1) | CL2007003830A1 (OSRAM) |
| CO (1) | CO6190613A2 (OSRAM) |
| CR (1) | CR10846A (OSRAM) |
| CY (1) | CY1116350T1 (OSRAM) |
| DK (1) | DK2114405T3 (OSRAM) |
| EC (1) | ECSP099471A (OSRAM) |
| ES (1) | ES2535040T3 (OSRAM) |
| HR (1) | HRP20150573T1 (OSRAM) |
| HU (1) | HUE025032T2 (OSRAM) |
| MA (1) | MA31029B1 (OSRAM) |
| MX (1) | MX2009006859A (OSRAM) |
| MY (1) | MY188367A (OSRAM) |
| NO (1) | NO342150B1 (OSRAM) |
| NZ (1) | NZ577502A (OSRAM) |
| PE (1) | PE20081556A1 (OSRAM) |
| PL (1) | PL2114405T3 (OSRAM) |
| PT (1) | PT2114405E (OSRAM) |
| RS (1) | RS53910B1 (OSRAM) |
| RU (1) | RU2463295C2 (OSRAM) |
| SI (1) | SI2114405T1 (OSRAM) |
| TW (1) | TWI388552B (OSRAM) |
| UA (1) | UA100232C2 (OSRAM) |
| WO (1) | WO2008080821A1 (OSRAM) |
| ZA (1) | ZA200904423B (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2673667A1 (en) | 2006-12-28 | 2008-07-10 | F. Hoffmann-La Roche Ag | Crystalline forms glyt1 |
| EP2400848A4 (en) * | 2009-02-26 | 2012-07-25 | Thar Pharmaceuticals Inc | CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS |
| KR101196354B1 (ko) * | 2010-09-03 | 2012-11-01 | 서유헌 | 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물 |
| JP2015518841A (ja) * | 2012-05-25 | 2015-07-06 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | １，５−ジメチル−６−チオキソ−３−（２，２，７−トリフルオロ−３−オキソ−４−（プロピ−２−イニル）−３，４−ジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−６−イル）−１，３，５−トリアジナン−２，４−ジオンの結晶形態Ｂ |
| US8927412B1 (en) * | 2013-08-01 | 2015-01-06 | Taiwan Semiconductor Manufacturing Company, Ltd. | Multi-chip package and method of formation |
| MX354615B (es) * | 2013-10-02 | 2018-03-08 | Centro De Investig Y De Estudios Avanzados Del I P N | Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus. |
| CN115279372A (zh) | 2020-01-09 | 2022-11-01 | 迪斯克医药公司 | 用甘氨酸转运蛋白抑制剂治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
| JP7096957B2 (ja) * | 2020-07-13 | 2022-07-06 | 日本碍子株式会社 | 精製方法 |
| EP4337199A4 (en) * | 2021-05-14 | 2025-03-19 | Disc Medicine, Inc. | Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents |
| US20240390362A1 (en) * | 2021-05-27 | 2024-11-28 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with a solid form of bitopertin |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| DK1656361T3 (da) * | 2003-08-11 | 2008-05-05 | Hoffmann La Roche | Piperazin med OR-substitueret phenylgruppe og anvendelse deraf som GLYT1-inhibitorer |
| CA2673667A1 (en) | 2006-12-28 | 2008-07-10 | F. Hoffmann-La Roche Ag | Crystalline forms glyt1 |
-
2007
- 2007-12-18 CA CA002673667A patent/CA2673667A1/en not_active Abandoned
- 2007-12-18 KR KR1020097015643A patent/KR101130146B1/ko active Active
- 2007-12-18 MX MX2009006859A patent/MX2009006859A/es active IP Right Grant
- 2007-12-18 WO PCT/EP2007/064104 patent/WO2008080821A1/en not_active Ceased
- 2007-12-18 JP JP2009543441A patent/JP4799666B2/ja active Active
- 2007-12-18 AU AU2007341356A patent/AU2007341356B2/en active Active
- 2007-12-18 BR BRPI0720829A patent/BRPI0720829B8/pt active IP Right Grant
- 2007-12-18 MY MYPI20092584A patent/MY188367A/en unknown
- 2007-12-18 SI SI200731644T patent/SI2114405T1/sl unknown
- 2007-12-18 PL PL07857734T patent/PL2114405T3/pl unknown
- 2007-12-18 NZ NZ577502A patent/NZ577502A/en unknown
- 2007-12-18 RS RS20150229A patent/RS53910B1/sr unknown
- 2007-12-18 HU HUE07857734A patent/HUE025032T2/en unknown
- 2007-12-18 EP EP07857734.3A patent/EP2114405B1/en active Active
- 2007-12-18 PT PT78577343T patent/PT2114405E/pt unknown
- 2007-12-18 RU RU2009124113/04A patent/RU2463295C2/ru active
- 2007-12-18 UA UAA200907731A patent/UA100232C2/uk unknown
- 2007-12-18 CN CNA2007800479512A patent/CN101573114A/zh active Pending
- 2007-12-18 HR HRP20150573TT patent/HRP20150573T1/hr unknown
- 2007-12-18 DK DK07857734T patent/DK2114405T3/en active
- 2007-12-18 ES ES07857734.3T patent/ES2535040T3/es active Active
- 2007-12-19 US US12/002,997 patent/US20080214561A1/en not_active Abandoned
- 2007-12-25 TW TW096150002A patent/TWI388552B/zh active
- 2007-12-27 CL CL200703830A patent/CL2007003830A1/es unknown
- 2007-12-27 AR ARP070105913A patent/AR064545A1/es not_active Application Discontinuation
-
2008
- 2008-01-02 PE PE2008000055A patent/PE20081556A1/es not_active Application Discontinuation
-
2009
- 2009-06-08 CR CR10846A patent/CR10846A/es unknown
- 2009-06-11 CO CO09061117A patent/CO6190613A2/es not_active Application Discontinuation
- 2009-06-19 NO NO20092358A patent/NO342150B1/no unknown
- 2009-06-24 ZA ZA200904423A patent/ZA200904423B/xx unknown
- 2009-06-26 EC EC2009009471A patent/ECSP099471A/es unknown
- 2009-06-29 MA MA32049A patent/MA31029B1/fr unknown
-
2010
- 2010-07-22 US US12/841,195 patent/US8039473B2/en not_active Expired - Fee Related
-
2011
- 2011-07-22 US US13/188,486 patent/US20110295007A1/en not_active Abandoned
-
2012
- 2012-06-13 US US13/495,093 patent/US20120309969A1/en not_active Abandoned
-
2013
- 2013-03-13 US US13/798,358 patent/US20130197225A1/en not_active Abandoned
-
2015
- 2015-05-20 CY CY20151100451T patent/CY1116350T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1116350T1 (el) | Mopφh συνκρυσταλλου «α» της [4-(3-φθορο-5-τριφθορομεθυλο-πυριδιν-2-υλο)-πιπεραζιν-1-υλο]-[5-μεθανοσουλφονυλο-2-((s)-2,2,2-τριφθορο-1-μεθυλο-αιθοξυ)-φαινυλο]-μεθανονης με μεθυλοπαραμπεν | |
| TW200700068A (en) | Phthalazine, aza-and diaza-phthalazine compounds and methods of use | |
| NO20060768L (no) | 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser | |
| EA200901373A1 (ru) | Аминогетероциклические соединения | |
| CY1111316T1 (el) | Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης | |
| BRPI0413497B8 (pt) | piperazina com ou que substitui grupo fenila, e seu uso e seu processo de preparação, bem como medicamento | |
| CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
| BRPI0415833A (pt) | derivados de triaza-espiropiperidina para uso como inibidores de glyt-1 no tratamento de distúrbios neurológicos e neuropsiquiátricos | |
| ATE411985T1 (de) | Substituierte piperazine als modulatoren des melanocortinrezeptors | |
| MY141229A (en) | Piperidine-benzenesulfonamide derivatives | |
| CY1113039T1 (el) | Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο | |
| WO2008045393A3 (en) | Imidazo- and triazolo-pyridine compounds and methods of use therof | |
| CY1112703T1 (el) | Υποκατεστημενες πιπεριδινο-διϋδρο-θειενο-πυριμιδινες | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| HRP20050933A2 (en) | Organic compounds | |
| MX387729B (es) | Derivados de dióxido de 1,4-tiazina y dióxido 1,2,4-tiadiazina como inhibidores de beta-secretasa y métodos de uso. | |
| MX2009014001A (es) | Derivados de isoxazol-imidazol. | |
| NZ593279A (en) | Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors | |
| MXPA05004273A (es) | Derivados de fenilalquil y piridilalquil piperazina. | |
| ATE445617T1 (de) | Chinolinderivat, dessen verwendung, herstellung und dieses enthaltendes arzneimittel | |
| TW200714282A (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
| ATE407126T1 (de) | Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on | |
| EA200870492A1 (ru) | N-оксиды производных пиридилметилпиперазина и - пиперидина | |
| TH92210B (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) | |
| TH107358A (th) | รูปผลึกร่วมเมธิลพาราเบน A ของ [4-(3-ฟลูออโร-5-ไตรฟลูออโรเมธิล-ไพริดิน-2-อิล)- พิเพอราซิน-1-อิล]-[5-มีเธนซัลโฟนิล-2-((S)-2,2,2-ไตรฟลูออโร-1-เมธิล-เอธอกซี)-ฟีนิล]-เมธาโนน ([4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone) |